Skip to content
lifestyle.lamora.net
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Protagenic Therapeutics, Inc.
Protagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety Disorder
November 11, 2026
Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
August 20, 2026
Protagenic Therapeutics’ Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
June 30, 2026
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
June 5, 2026